Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis : Episode 9
Opinion
Video
Typical Payer Coverage Criteria for Multiple Sclerosis Therapies
Author(s):
Heidi Crayton, MD, discusses the typical coverage criteria requirements she encounters from payers for currently-approved therapies for multiple sclerosis.
EP: 1.Teaser: Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis
EP: 2.Multiple Sclerosis: Impact, Types, Pathophysiology, and Progression
EP: 3.Assessing Limitations, Costs, Mobility and Cognition in Progressive Multiple Sclerosis
EP: 4.Examining Key Unmet Needs in Multiple Sclerosis
EP: 5.Patient Satisfaction: Opportunity for Better Multiple Sclerosis Therapies
EP: 6.MS Treatment Guidelines: Expert Insights on Updates and Decision-Making
EP: 7.Incorporating a Subcutaneous Novel Therapy into Multiple Sclerosis Treatment
EP: 8.Examining Challenges with Drug Switching and Step Therapy in MS Treatment
Now Viewing
EP: 9.Typical Payer Coverage Criteria for Multiple Sclerosis Therapies
EP: 10.BTK Inhibitors' Rationale and Potential Role in Multiple Sclerosis Treatment
EP: 11.Updates in Recent Clinical Trials in the Treatment of Multiple Sclerosis
EP: 12.Primary Progressive Multiple Sclerosis Treatment Landscape: Emerging Therapies
EP: 13.Multiple Sclerosis: Looking Toward the Future
Video content above is prompted by the following questions:
- What typical coverage criteria requirements are you seeing from payers with currently-approved therapies for multiple sclerosis (MS)?
- Do you see benefit of ICD-10 coding by different MS phenotypes vs. having only one code?
Related Videos
Related Content
